Chugai and Biofourmis Enter into New Partnership Focused on Data-Driven Virtual Care for Endometriosis-Related Pain

Chugai Pharmaceutical and Biofourmis have partnered to continue developing digital solutions to measure pain in patients with endometriosis using a biosensor and an AI-based algorithm. The collaboration will focus on the continued development of pain measurement technology for endometriosis patients, advancing a technology platform for real-world data-driven pain measurement, and virtual specialty care delivery for endometriosis patients in the US. The partnership will also utilize data collected during research and development and post-marketing of Chugai’s investigational product for the treatment of endometriosis pain. This collaboration aims to enhance Chugai’s value proposition for endometriosis patients and deliver new value to patients as part of the company’s growth strategy.